Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17416625 | 0.92 | ABCB1 (0.52) | ABCB1NPC1RAB9A | |
| SCHEMBL14688168 | 0.91 | ABCB1 (0.43) | ABCB1NPC1RAB9A | |
| SCHEMBL9232983 | 0.90 | ABCB1 (0.48) | ABCB1NPC1RAB9ACYP3A4 | |
| SCHEMBL9101226 | 0.89 | ABCB1 (0.47) | ABCB1NPC1RAB9ACYP3A4 | |
| SCHEMBL9105189 | 0.89 | ABCB1 (0.43) | ABCB1NPC1RAB9A | |
| SCHEMBL17416624 | 0.87 | ABCB1 (0.53) | ABCB1NPC1RAB9A | |
| SCHEMBL7067587 | 0.86 | ABCB1 (0.64) | ABCB1NPC1RAB9A | |
| SCHEMBL17416629 | 0.86 | CTSD (0.43) | NPC1RAB9A | |
| SCHEMBL18091865 | 0.86 | NPC1 (0.48) | ABCB1NPC1RAB9ACYP3A4 | |
| SCHEMBL9100311 | 0.86 | RAB9A (0.43) | ABCB1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170096672-A1 | Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System | INTREXON CORPORATION (US) | 2017-04-06 | — | — | US | disclosed |
| EP-2374891-A2 | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system | Intrexon Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096672-A1 | Novel Ecdysone Receptor/Invertebrate Retinoid X Receptor-Based Inducible Gene Expression System | NR2E3, RXRA, RXRB | ABCB1 2298/4885NPC1 2271/4885RAB9A 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.